More than 40,000 Cancer Claims Remain Unresolved from Proposed Bayer Monsanto Roundup Weed Killer Lawsuit Settlement

Rhea-AI Summary

As of April 26, 2021, over 40,000 claims regarding non-Hodgkin's lymphoma linked to Bayer's Roundup herbicide remain unsettled. Plaintiffs argue that the proposed settlement is unfair and favor jury trials for justice. The Fears Nachawati Law Firm aims to discard the settlement, which permits Bayer to negotiate with law firms individually, potentially leading to lower compensation for remaining cancer claims. Glyphosate, the active ingredient in Roundup, has been associated with cancer, resulting in multimillion-dollar verdicts against Bayer in previous trials.

Positive

• Previous jury trials resulted in multimillion-dollar verdicts against Bayer, indicating the potential strength of claims.
• The litigation process could lead to further negotiations that might benefit some claimants.

Negative

• More than 40,000 unresolved claims indicate ongoing legal exposure and liabilities for Bayer.
• The proposed settlement framework has been criticized as inconsistent and unfair, leading to potential prolonged litigation.
• The structure of the settlement allows for separate negotiations, which may disadvantage remaining claimants financially.

DALLAS, April 26, 2021 /PRNewswire/ -- More than 40,000 current claims on behalf of individuals diagnosed with non-Hodgkins lymphoma after exposure to the Bayer Monsanto Roundup herbicide remain unresolved as criticism mounts that a proposed settlement framework is inconsistent and unfair to cancer victims.

Plaintiffs in multidistrict litigation (MDL) against Roundup maker Bayer AG (OTCMKTS: BAYRY) increasingly see a jury trial as the only avenue for justice, said trial lawyer Majed Nachawati of Dallas-based Fears Nachawati Law Firm.

The Fears Nachawati Law Firm has filed motions on behalf of clients with non-Hodgkins lymphoma seeking to throw out a proposed settlement to the MDL, which would allow Roundup maker Bayer AG to continue selling the glyphosate-based herbicide while shielding it from future cancer lawsuits.

"This proposed settlement has been fatally flawed from the beginning," Mr. Nachawati said. "Bayer shareholders would like to put this significant exposure behind them, however Bayer's strategy will only ensure that jury trials will take place for years to come."

Rather than resolving all the lawsuits together, the proposed settlement allows Bayer's lawyers to negotiate separately with one law firm at a time. According to published reports, law firms that were part of the MDL leadership committee were among the first to settle and reached agreements that are more than twice the amount the remaining cancer claims are being offered. 

Roundup's active ingredient, glyphosate, has been linked in published reports to the development of non-Hodgkin's lymphoma and other forms of cancer. Juries in three separate trials heard the evidence and returned multimillion-dollar verdicts against Bayer AG, which acquired Roundup-maker Monsanto in 2018.  

The multidistrict litigation (MDL) is In re: Bayer Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California. 

Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation and individual victims in complex personal injury litigation. The largest and most diverse products liability law firm in the nation, Fears | Nachawati was ranked No. 1 nationally in product liability filings in federal court over the last three years. For more information, visit https://www.fnlawfirm.com.

Media Contact:  
Robert Tharp  
214-420-6011  
robert@androvett.com  

 

View original content:http://www.prnewswire.com/news-releases/more-than-40-000-cancer-claims-remain-unresolved-from-proposed-bayer-monsanto-roundup-weed-killer-lawsuit-settlement-301276971.html

SOURCE Fears Nachawati Law Firm

FAQ

What is the status of the Bayer Roundup lawsuit as of April 2021?

As of April 2021, over 40,000 claims related to non-Hodgkin's lymphoma due to Roundup remain unresolved.

How has Bayer's proposed settlement been received by plaintiffs?

Plaintiffs have criticized the proposed settlement as inconsistent and unfair, favoring a jury trial instead.

What legal strategy is being pursued by the Fears Nachawati Law Firm in the Roundup litigation?

The Fears Nachawati Law Firm seeks to discard the proposed settlement, aiming for jury trials for their clients.

What are the implications of the unresolved claims on Bayer's stock?

The unresolved claims may pose ongoing legal risks and uncertainties affecting Bayer's stock performance.

What has been the outcome of previous trials related to Bayer and Roundup?

Previous trial outcomes included multimillion-dollar verdicts against Bayer for non-Hodgkin's lymphoma cases.